Euclid Biosciences Inc is categorized under Commercial Biotechnical Research in Chicago, IL and active since 2003.
Euclid Biosciences Inc was established in 2003, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Igor Brikun at the company’s single location by writing to 2201 West Campbell Park Drive D, Chicago, Illinois IL 60612 or by phoning (708) 557-6506. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Euclid Biosciences Inc |
| Contact Person: | Igor Brikun |
| Address: | 2201 West Campbell Park Drive D, Chicago, Illinois 60612 |
| Phone Number: | (708) 557-6506 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2003 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Euclid Biosciences Inc was started in 2003 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Igor Brikun for inquiries that concern Euclid Biosciences Inc by calling the company number (708) 557-6506, as your correspondence is most welcome. Additionally, the physical location of the single location of Euclid Biosciences Inc can be found at the coordinates 41.872403,-87.681514 as well as the street address 2201 West Campbell Park Drive D in Chicago, Illinois 60612.
For its online presence, you may visit Euclid Biosciences Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.